《公司业绩》非凡中国(08032.HK)全年纯利8.34亿元升983.8%
非凡中国(08032.HK)公布截至去年12月底止全年业绩,营业额6.25亿元,按年跌44.9%。纯利8.34亿元,按年升983.8%,主要由於年内出售一间联营公司(李宁公司)之6.8%权益而产生之收益8.174亿元,以及分占联营公司及合营企业之净溢利增加1.598亿港元;每股盈利7.41仙。不派息。
今年新型冠状病毒肺炎蔓延全球,公司预料疫情将对集团主营业务,尤其是体育目的地的营运及发展带来若干影响。鉴於集团的财务状况一直维持稳健,并及时积极采取相关的应对措施,因此不会出现系统性问题,疫情过後业务营运将恢复正常。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.